Eris Lifesciences Limited (BOM:540596)
India · Delayed Price · Currency is INR 1,679.10
-43.75 (-2.54%)
At close: Aug 12, 2025
Eris Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 3,518 | 3,921 | 3,822 | 4,061 | 3,551 | Upgrade |
Depreciation & Amortization | - | 3,124 | 1,797 | 1,144 | 626.21 | 423.02 | Upgrade |
Other Amortization | - | 30.6 | 28.2 | 26.58 | 20.84 | 6.83 | Upgrade |
Loss (Gain) From Sale of Assets | - | 9.2 | 21.4 | 20.18 | 42.54 | 0.06 | Upgrade |
Loss (Gain) From Sale of Investments | - | -30 | -93.8 | -69.33 | -167.61 | -49.77 | Upgrade |
Stock-Based Compensation | - | 91.3 | 7.5 | 31.21 | 13.55 | 11.2 | Upgrade |
Provision & Write-off of Bad Debts | - | - | - | 0.67 | 0.02 | 65.1 | Upgrade |
Other Operating Activities | - | 2,647 | 166.8 | -302.45 | -515.03 | -307.45 | Upgrade |
Change in Accounts Receivable | - | -91.1 | -570.9 | -1,171 | -204.8 | 158.96 | Upgrade |
Change in Inventory | - | -943.6 | -169.4 | 47.44 | -234.45 | -249.91 | Upgrade |
Change in Accounts Payable | - | 679.4 | 909.8 | -104.97 | 151.59 | 25.66 | Upgrade |
Change in Other Net Operating Assets | - | 1,615 | -1,157 | -526.45 | -11.35 | 118.56 | Upgrade |
Operating Cash Flow | - | 10,650 | 4,860 | 2,917 | 3,783 | 3,754 | Upgrade |
Operating Cash Flow Growth | - | 119.13% | 66.59% | -22.88% | 0.77% | 38.42% | Upgrade |
Capital Expenditures | - | -1,550 | -1,292 | -8,414 | -1,210 | -257.63 | Upgrade |
Sale of Property, Plant & Equipment | - | 3.7 | - | 1.37 | 7.58 | 0.38 | Upgrade |
Cash Acquisitions | - | -11,690 | -5,668 | -6,555 | - | - | Upgrade |
Investment in Securities | - | -484.3 | 484.1 | 4,904 | -1,881 | -2,946 | Upgrade |
Other Investing Activities | - | 12,923 | -12,053 | 35.61 | 49.32 | -0.4 | Upgrade |
Investing Cash Flow | - | -799.7 | -18,545 | -9,821 | -3,196 | -3,234 | Upgrade |
Long-Term Debt Issued | - | 14,364 | 16,231 | 11,678 | 450.01 | 0.1 | Upgrade |
Long-Term Debt Repaid | - | -18,424 | -1,603 | -3,587 | -115.01 | -59.45 | Upgrade |
Total Debt Repaid | - | -18,424 | -1,603 | -3,587 | -115.01 | -59.45 | Upgrade |
Net Debt Issued (Repaid) | - | -4,059 | 14,628 | 8,091 | 335 | -59.35 | Upgrade |
Issuance of Common Stock | - | 72.2 | 45.4 | 22.78 | 71.96 | - | Upgrade |
Common Dividends Paid | - | -1,001 | - | -999.11 | -816.23 | -746.79 | Upgrade |
Other Financing Activities | - | -3,826 | -875.7 | -234.3 | -37.72 | -17.81 | Upgrade |
Financing Cash Flow | - | -8,813 | 13,798 | 6,880 | -446.99 | -823.95 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | 17.7 | 269.6 | 74.9 | - | - | Upgrade |
Net Cash Flow | - | 1,055 | 382.3 | 51.52 | 139.55 | -303.92 | Upgrade |
Free Cash Flow | - | 9,100 | 3,569 | -5,497 | 2,572 | 3,496 | Upgrade |
Free Cash Flow Growth | - | 155.01% | - | - | -26.42% | 191.61% | Upgrade |
Free Cash Flow Margin | - | 31.61% | 17.92% | -33.08% | 19.40% | 29.31% | Upgrade |
Free Cash Flow Per Share | - | 66.77 | 26.21 | -40.37 | 18.93 | 25.73 | Upgrade |
Cash Interest Paid | - | 1,451 | 773 | 234.3 | 38.5 | 17.81 | Upgrade |
Cash Income Tax Paid | - | 978.8 | 1,008 | 772.08 | 832.85 | 685.35 | Upgrade |
Levered Free Cash Flow | - | 6,527 | 2,357 | -6,892 | 1,623 | 2,560 | Upgrade |
Unlevered Free Cash Flow | - | 7,973 | 2,887 | -6,729 | 1,649 | 2,571 | Upgrade |
Change in Working Capital | - | 1,260 | -987.4 | -1,755 | -299.01 | 53.27 | Upgrade |
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.